Existing investor Bioventus has returned to reinvest in the bone implant provider, whose existing backers include Johnson & Johnson Innovation – JJDC.
Israel-based orthobiologic medical device provider CartiHeal raised $15m from orthopaedic biosurgery product manufacturer Bioventus yesterday.
CartiHeal produces bone implants for cartilage and osteochondral injuries in the knee joints. More than 400 patients in Europe and Israel have used the product but it is not yet available in the United States, where it is undergoing an investigational device exemption (IDE) clinical trial.
The funding came in the wake of a cross-border IDE study, and Bioventus may provide an additional $5m for…
